U.S. markets open in 3 hours 50 minutes

Need To Know: Ascletis Pharma Inc. (HKG:1672) Insiders Have Been Buying Shares

Simply Wall St

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you buy or sell Ascletis Pharma Inc. (HKG:1672), you may well want to know whether insiders have been buying or selling.

What Is Insider Buying?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, such insiders must disclose their trading activities, and not trade on inside information.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Check out our latest analysis for Ascletis Pharma

The Last 12 Months Of Insider Transactions At Ascletis Pharma

In the last twelve months, the biggest single purchase by an insider was when Founder Jinzi Jason Wu bought HK$3.5m worth of shares at a price of HK$3.05 per share. That implies that an insider found the current price of HK$3.42 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider bought shares at close to current prices. Jinzi Jason Wu was the only individual insider to buy shares in the last twelve months.

Jinzi Jason Wu bought 2.31m shares over the last 12 months at an average price of HK$3.02. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

SEHK:1672 Recent Insider Trading May 20th 2020

Ascletis Pharma is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership of Ascletis Pharma

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Ascletis Pharma insiders own about HK$2.0b worth of shares (which is 54% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At Ascletis Pharma Tell Us?

It doesn't really mean much that no insider has traded Ascletis Pharma shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. Judging from their transactions, and high insider ownership, Ascletis Pharma insiders feel good about the company's future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. While conducting our analysis, we found that Ascletis Pharma has 1 warning sign and it would be unwise to ignore this.

Of course Ascletis Pharma may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.